Abbott recently announced the the U.S. Food and Drug Administration (FDA) cleared the Advisor™ HD Grid Mapping Catheter, Sensor Enabled™, which has first-of-its-kind grid configuration, designed to capture data in multiple directions and to create high-density maps of the heart.
Editor's Note: This article originally appeared on Abbott's website.
ABBOTT PARK, Ill., May 3, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) clearance of the Advisor™ HD Grid Mapping Catheter, Sensor Enabled™. Advisor HD Grid employs a new design that allows physicians to see things differently, capturing and analyzing data in a novel manner to create highly detailed maps of the heart that better differentiate healthy from unhealthy tissue. The new mapping catheter builds upon Abbott's innovative products designed to improve how physicians perform cardiac ablation procedures, including the EnSite Precision Cardiac Mapping System and a broad range of mapping and treatment catheters. Click here to continue >>
News from our partners